



CIN : L99999MH1951PLC008485

Regd. Office : A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India

Tel : +91-22-67980888 , ● Fax : +91-22-67980899 , ● Email : contact@dil.net , ● Website: www.dil.net

Ref: DIL:DIL/BSE/2018-19/F.No.:S-23/ DE05

August 14, 2018

Corporate Relations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001

Dear Sir,

Sub.: Intimation of Earnings Release dated August 14, 2018

Ref: Scrip Code: 506414

Further to our intimation dated August 14, 2018 regarding approval of Unaudited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter ended June 30, 2018, we hereby enclose a copy of Earnings Release of the Company dated August 14, 2018 for the quarter ended June 30, 2018.

The said Earnings Release is also available on Company's website www.dil.net

Kindly take the same on records.

Thanking you,

Yours faithfully,
for **DIL LIMITED**

Srikant N Sharma
Company Secretary

CS Membership No: F3617

A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610

Encl: As above

DIL Limited

Q1FY19 Consolidated Performance:

- Total Revenue (including other income) up by 89% YoY to Rs. 83.45 Cr
- EBITDA (including other income) grew by 1,351% YoY to Rs. 29.17 Cr, margin is at 35%
- PAT grew by 550% YoY to Rs. 16.68 Cr

Mumbai – 14th August 2018 – Results of Fermenta Biotech Limited, 91.2% Subsidiary of DIL Limited

Fermenta Biotech Limited (FBL) manufactures Vitamin D3 (Cholecalciferol), the only manufacturer and supplier in India and amongst the top few manufacturers in the world. Apart from Vitamin D3, it also manufactures niche APIs, and is a major supplier of Penicillin G Amidase, Polymer supports and Enzyme technologies for beta lactams and Bio-Enzymes for environmental solutions.

Fermenta Biotech Limited				
Particulars (Rs. Crs)	Q1 FY19	Q1 FY18	YoY%	FY18
Revenue*	79.74	42.31	88%	300.48
EBITDA*	28.67	4.26	574%	103.19
Margin (%)	36%	10%		34%
PAT	21.10	1.13	1,772%	72.06
Margin (%)	26%	3%		24%

*includes other income

- The revenue (including other income) stood at Rs. 79.74 Cr for Q1FY19 as against Rs.42.31 Cr in Q1FY18 up by 88% YoY led by increase in volumes of Vitamin D3 segment and better realizations
- EBITDA margins stands at 36% for Q1FY19 as against 10% in Q1FY18. The expansion in margins has largely been on the account of improvement in realizations
- PAT for Q1FY19 stood at Rs.21.10 Cr; growth of 1,772% YoY

Earnings Release

Un-audited Consolidated Results of DIL Limited:

DIL Limited (Consolidated Results)				
Particulars (Rs. Crs)	Q1 FY19	Q1 FY18	YoY%	FY18
Revenue*	83.45	44.10	89%	311.92
EBITDA*	29.17	2.01	1,351%	101.96
Margin (%)	35%	5%		33%
PAT	16.68	(3.71)	550%	54.84
Margin (%)	21%	-		18%

*includes other income

Commenting on the performance Mr. Satish Varma, Managing Director, Fermenta Biotech Limited said

“We began our Q1FY19 on a positive note and we believe that our growth momentum will continue during the year.

During the quarter the prices of Vitamin D3 remained stable across markets over the last few months. We have witnessed improved demand for Vitamin D3 across the markets on the back of increasing awareness of the importance of Vitamin D3 among the people.

Our EBITDA margins continue to remain in region of 35%.

Our efforts on R&D and production towards our Enzyme manufacturing is now yielding results. The total revenue in FY18 from Enzyme business was Rs. 3.11 Crores and the same in Q1FY19 has clocked revenue of Rs. 3.34 Crores.

Our capacity utilisations have been improving over the last few quarters and pursuing our growth strategy we shall continue to invest in enhancing our manufacturing capacities.”

Earnings Release

About DIL Limited:

DIL holds 91.2% equity stake in Fermenta Biotech Limited (FBL), which was incorporated in 1986.

FBL is engaged in manufacturing of Vitamin D3, other specialty APIs, biological enzymes and also offers integrated biotech based environmental solutions. FBL has 2 manufacturing facilities:

- Kullu in Himachal Pradesh – cGMP certified and currently manufactures Vitamin D3, specialty API's and Enzymes
- Dahej SEZ – set up in 2011 and manufactures Vitamin D3

DIL has developed premium office spaces named 'THANE ONE', with a total leasable area of 200,000 sq. ft., which is currently about 95% occupied.

For more information about the Company and its businesses, please visit our website www.dil.net

Safe Harbor:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company	Investor Relations Advisors
<p>DIL Limited CIN No: L99999MH1951PLC008485 Name: Sumesh Gandhi Email id: sumesh.gandhi@dil.net</p>	<p>Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Rahul Agarwal / Nirali Shah Email id: rahul.agarwal@sgapl.net Nirali.shah@sgapl.net Tel No: +91 79770 90416 / +91 97736 17347</p>